Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01975701 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT01975701 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT01975701, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is an open-label non-randomized, multicenter, phase II study of BGJ398 administered to adult patients with histologically confirmed GBM and/or other glioma subtypes with FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutation in FGFR1, 2 or 3.
Interventions
- DRUG BGJ398
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-12-09 |
| Est. Completion | 2018-10-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01975701
The ClinicalTrials.gov registry entry for NCT01975701 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BGJ398 is the first listed.
NCT01975701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01975701 about?
NCT01975701 is a clinical study titled "A Phase 2 Study of BGJ398 in Patients With Recurrent GBM". This is an open-label non-randomized, multicenter, phase II study of BGJ398 administered to adult patients with histologically confirmed GBM and/or other glioma subtypes with FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutation in FGFR1, 2 or 3.
What is the current status of trial NCT01975701?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2013-12-09. Estimated completion is 2018-10-03.
What interventions are being tested in trial NCT01975701?
The interventions under investigation include: BGJ398 (DRUG).
Who is sponsoring clinical trial NCT01975701?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.